Christina Anna Stratopoulou

Dr. Christina Anna Stratopoulou

Center for Reproductive Medicine and Infertility, Weill Cornell Medicine, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RKRadhika Kapoor
Radhika Kapoor
Christina Anna StratopoulouChristina Anna Stratopoulou
Christina Anna Stratopoulou
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans
Endometriosis is a female reproductive disorder characterized by growth of uterine cells and tissue in distant sites. Around 2–10% of women experience this condition during reproductive age, 35–50% of whom encounter fertility issues or pain. To date, there are no established methods for its early diagnosis and treatment, other than surgical procedures and scans. It is difficult to identify the disease at its onset, unless symptoms such as infertility and/or pain are present. Determining the mechanisms involved in its pathogenesis is vital, not only to pave the way for early identification, but also for disease management and development of less invasive but successful treatment strategies. Endometriosis is characterized by cell proliferation, propagation, evasion of immunosurveillance, and invasive metastasis. This review reports the underlying mechanisms that are individually or collectively responsible for disease establishment and evolution. Treatment of endometriosis mainly involves hormone therapies, which may be undesirable or have their own repercussions. It is therefore important to devise alternative strategies that are both effective and cause fewer side effects. Use of phytochemicals may be one of them. This review focuses on pharmacological inhibitors that can be therapeutically investigated in terms of their effects on signaling pathways and/or mechanisms involved in the pathogenesis of endometriosis.

5 December 2023 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Closed access
JDJacques Donnez
Jacques Donnez
Christina Anna StratopoulouChristina Anna Stratopoulou
Christina Anna Stratopoulou
MDMarie-Madeleine Dolmans
Marie-Madeleine Dolmans

22 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Christina Anna StratopoulouChristina Anna Stratopoulou
Christina Anna Stratopoulou
JDJacques Donnez
Jacques Donnez
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans
Uterine adenomyosis is a commonly encountered estrogen-dependent disease in reproductive-age women, causing heavy menstrual bleeding, intense pelvic pain, and infertility. Although adenomyosis was previously considered a disease of multiparous women, it is becoming increasingly evident that it also affects younger nulliparous women and may compromise their fertility potential. It is clear that hysterectomy, the standard approach to definitively manage the disease, is not an option for patients wishing to preserve their fertility, so there is an urgent need to develop novel conservative strategies. We searched the current literature for available methods for conservative management of adenomyosis, including both pharmacological and surgical approaches. There is no existing drug that can cure adenomyosis at present, but some off-label treatment options may be used to tackle disease symptoms and improve fertility outcomes. Adenomyosis in patients wishing to conceive can be ‘treated’ by conservative surgery, though these procedures require highly experienced surgeons and pose a considerable risk of uterine rupture during subsequent pregnancies. While currently available options for conservative management of adenomyosis do have some capacity for alleviating symptoms and enhancing patient fertility perspectives, more effective new options are needed, with gonadotropin-releasing hormone antagonists showing encouraging results in preliminary studies.

22 October 2020 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
Christina Anna StratopoulouChristina Anna Stratopoulou
Christina Anna Stratopoulou
JDJacques Donnez
Jacques Donnez
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans

JDJacques Donnez
Jacques Donnez
Christina Anna StratopoulouChristina Anna Stratopoulou
Christina Anna Stratopoulou
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans
Uterine adenomyosis is a common chronic disorder frequently encountered in reproductive-age women, causing heavy menstrual bleeding, intense pelvic pain, and infertility. Despite its high prevalence, its etiopathogenesis is not yet fully understood, so there are currently no specific drugs to treat the disease. A number of dysregulated mechanisms are believed to contribute to adenomyosis development and symptoms, including sex steroid signaling, endometrial proliferation and invasiveness, and aberrant immune response. Abnormal sex steroid signaling, particularly hyperestrogenism and subsequent progesterone resistance, are known to play a pivotal role in its pathogenesis, which is why various antiestrogenic agents have been used to manage adenomyosis-related symptoms. Among them, gonadotropin-releasing hormone (GnRH) antagonists are swiftly gaining ground, with recent studies reporting efficient lesion regression and symptom alleviation. The aim of the present review is to compile available information on the pathogenesis of adenomyosis, explore the etiology and mechanisms of hyperestrogenism, and discuss the potential of antiestrogenic therapies for treating the disease and improving patient quality of life.

9 January 2023 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
Christina Anna StratopoulouChristina Anna Stratopoulou
Christina Anna Stratopoulou
SCSophie Cussac
Sophie Cussac
MDMarie D'ARgent
Marie D'ARgent
JDJacques Donnez
Jacques Donnez
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans